SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Valuation Spotlight as Leadership Transition Signals Strategic Shift

Everest Medicines (SEHK:1952) is set for a transition at the top, as Wei Fu steps down as chairman to focus on other commitments. Yifang Wu, a seasoned veteran from Fosun Pharma, will take the helm starting October 10, 2025. See our latest analysis for Everest Medicines. Investors seem to be weighing Everest Medicines’ leadership shake-up against its strong recent momentum, with the share price up 4% in the past day and 7% year-to-date. Despite short-term volatility, the company's one-year...
SEHK:3908
SEHK:3908Capital Markets

A Look at China International Capital (SEHK:3908) Valuation Following Major Governance Restructuring Proposal

China International Capital (SEHK:3908) has proposed a vote to eliminate its Supervisory Committee and amend its Articles of Association at the upcoming annual meeting on October 31, 2025. This move signals a shift in the corporate governance structure. See our latest analysis for China International Capital. Investors seem upbeat about China International Capital’s bold governance overhaul, with the share price up 78% year-to-date and a standout three-year total shareholder return of 110%...
SEHK:1199
SEHK:1199Infrastructure

COSCO SHIPPING Ports (SEHK:1199): Valuation Insights After Interim Dividend and Scrip Share Option Announcement

COSCO SHIPPING Ports (SEHK:1199) caught the market’s attention after announcing its first interim dividend for the year. Shareholders will have the option to take cash or scrip shares instead. This decision highlights the company’s flexible approach to rewarding investors. See our latest analysis for COSCO SHIPPING Ports. The upbeat mood around COSCO SHIPPING Ports has coincided with solid performance, as the stock logged a 25% year-to-date share price return and boasts a 1-year total...
SEHK:388
SEHK:388Capital Markets

Record ETF Turnover and Global Inflows Might Change the Case For Investing in Hong Kong Exchanges (SEHK:388)

Hong Kong Exchanges and Clearing reported that its exchange-traded fund (ETF) market achieved record average daily turnover of HK$37.8 billion in the first nine months of this year, alongside a rise in new ETF listings and strong investor interest from mainland China, Asia, the Middle East, and Europe. Growth in Hong Kong’s ETF market is fueled by enhanced international connectivity and the introduction of innovative products, such as virtual-asset and income-focused ETFs. We’ll explore how...
SEHK:1211
SEHK:1211Auto

Does BYD’s Share Price Drop Signal a New Opportunity for Investors in 2025?

If you are wondering whether BYD stock deserves a spot in your portfolio, you are definitely not alone. The company’s recent share price moves have given both bulls and bears something to talk about. After a dip of 1.4% over the past week and an 8.5% decline in the last month, it is tempting to ask if the market is recalibrating its view of BYD’s growth potential or simply reacting to short-term noise. Still, when you take a step back, the longer-term story looks remarkably strong, with...
SEHK:992
SEHK:992Tech

Will Lenovo’s New AI-Enabled Workforce Portfolio Transform the Investment Narrative for Lenovo Group (SEHK:992)?

Earlier this month, Lenovo unveiled a wide-ranging AI-Enabled Workforce portfolio featuring new agentic AI capabilities, integrating devices, services, and lifecycle solutions to help enterprises realize measurable business value from AI investments. This initiative reflects a rising industry trend where organizations are moving from piloting AI tools to embedding automation across their workforces, with early adopters already reporting significant productivity and cost-efficiency...
SEHK:6990
SEHK:6990Biotechs

A Look at Kelun-Biotech (SEHK:6990) Valuation Following Breakthrough ADC Trial Results and New China Approvals

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is catching plenty of attention after unveiling positive late-stage trial results for its lead ADC therapies at the 2025 ESMO Congress. With both trastuzumab botidotin and sacituzumab tirumotecan outperforming standard treatments in breast and lung cancer, as well as new regulatory approvals in China, investors are taking a fresh look at the company’s commercial prospects. See our latest analysis for Sichuan Kelun-Biotech...
SEHK:2018
SEHK:2018Electronic

Does AAC Technologies Holdings' Share Buyback Authorization Signal Management’s Confidence in Per-Share Growth (SEHK:2018)?

On October 17, 2025, AAC Technologies Holdings commenced a share repurchase program, authorized at its May 22 Annual General Meeting, enabling buybacks of up to 117,518,750 shares, representing 10% of its issued share capital, using funds from profits or other legally available resources. This move aims to enhance net asset value and earnings per share, signaling management’s confidence and a commitment to improving per-share financial fundamentals. We’ll explore how initiating a substantial...
SEHK:941
SEHK:941Wireless Telecom

China Mobile (SEHK:941) Margin Improvement Reinforces Value Narrative Despite Growth Concerns

China Mobile (SEHK:941) posted a net profit margin of 13.7% in its latest results, slightly up from 13.4% last year, with earnings growing by 4.2% this year versus a 6% annual average over the past five years. The stock is currently trading at HK$85.2, putting its price-to-earnings multiple at 11.8x, well below both the Asian Wireless Telecom industry average of 19.5x and the peer group average of 16.5x. It is also below a fair value estimate of HK$243.83. Investors may see value in the...
SEHK:1109
SEHK:1109Real Estate

A Look at China Resources Land (SEHK:1109) Valuation After Latest Operating Update Highlights Recurring Revenue Strength

China Resources Land (SEHK:1109) just shared its operating results through September, revealing that although overall contracted sales and floor area dropped year-over-year, recurring revenue and rental income both moved higher. This hints at a resilient investment property business. See our latest analysis for China Resources Land. China Resources Land’s investment property strength appears to have caught investors’ attention, with shares up more than 34% year to date and a 20% total...
SEHK:3900
SEHK:3900Real Estate

Greentown China (SEHK:3900) Valuation: Fresh Insights Following Latest Operating Results Release

Greentown China Holdings (SEHK:3900) just released its unaudited operating results, providing detailed data on September and year-to-date sales volumes, sales area, and contracted sales across its projects. See our latest analysis for Greentown China Holdings. Greentown China Holdings’ release of robust September and year-to-date operating figures comes after a period of notable price volatility. The stock is trading at HK$8.93, and recent sales news has helped sentiment recover from a...
SEHK:512
SEHK:512Pharmaceuticals

Grand Pharmaceutical Group (SEHK:512): Valuation Insights Following Key Liver Cancer Drug Clinical Milestone

Grand Pharmaceutical Group (SEHK:512) has completed patient enrollment for its China registration clinical study of GPN00289, a next-generation embolic agent targeting primary liver cancer. This product represents an important step in expanding the company's oncology pipeline. See our latest analysis for Grand Pharmaceutical Group. It has been a transformative year for Grand Pharmaceutical Group, with its latest clinical milestone reflecting sustained momentum. The stock’s 84.33% total return...
SEHK:6699
SEHK:6699Medical Equipment

Angelalign Technology (SEHK:6699): Weighing Valuation After Pioneering 3D Printing Partnership With LuxCreo

Angelalign Technology (SEHK:6699) has taken a significant step in dental innovation by investing in LuxCreo and launching a global partnership. Together, they aim to advance 3D-printed aligner materials, increasing precision, flexibility, and patient comfort in orthodontics. See our latest analysis for Angelalign Technology. Angelalign’s move to team up with LuxCreo comes as its stock shows renewed momentum, with an 11.3% share price return over the past three months. Despite this, the...
SEHK:2343
SEHK:2343Shipping

Pacific Basin Shipping (SEHK:2343): Valuation in Focus After Board Changes Address US Regulatory Risks

Pacific Basin Shipping (SEHK:2343) has drawn renewed attention after announcing executive changes intended to address US regulatory risks. The board appointed Kristian Helt as executive Director, while Alexander Howarth Yat Kay Cheung resigned as Non-executive Director. See our latest analysis for Pacific Basin Shipping. Investor sentiment has been lively this year, with Pacific Basin Shipping’s share price climbing over 54% year-to-date and notching a 13.6% gain in the last 90 days, although...
SEHK:66
SEHK:66Transportation

MTR (SEHK:66) Valuation in Focus After Landmark Green Loan and Leadership Transition

MTR (SEHK:66) has just completed a significant HKD 30 billion syndicated green loan, marking its largest return to the Asia loan market in almost ten years. Investors are keeping a close eye on this strategic financing move. See our latest analysis for MTR. MTR’s record-setting green loan and a seamless leadership transition have put the company back in the market spotlight, and momentum seems to be cautiously returning. While the stock’s 1-year total return is down 1.3%, a steady share price...
SEHK:1810
SEHK:1810Tech

Xiaomi (SEHK:1810): Taking Stock of Valuation After Latest Share Price Rebound

Shares of Xiaomi (SEHK:1810) are in focus as investors look for signals in the company's recent market moves. With prices edging up by almost 3% in the last day, market watchers are curious about what might be driving sentiment. See our latest analysis for Xiaomi. This latest share price bump comes after a challenging stretch for Xiaomi, including a 16.9% drop over the past month. Still, momentum looks strong when you zoom out: the total shareholder return for the past year is an outstanding...
SEHK:1735
SEHK:1735Construction

Assessing Central New Energy Holding Group (SEHK:1735) Valuation After Strategic Green Methanol Partnership Announcement

Central New Energy Holding Group (SEHK:1735) just announced a strategic partnership with Jilin Province Huajin Energy. The focus is on developing green methanol and related new energy projects, which could broaden the company’s future opportunities. See our latest analysis for Central New Energy Holding Group. After some volatility earlier in the year, Central New Energy Holding Group’s 90-day share price return of 7.8% hints at growing optimism from investors, likely helped by its recent...
SEHK:1066
SEHK:1066Medical Equipment

Assessing Shandong Weigao Group (SEHK:1066) Valuation After Interim Dividend and Governance Amendments

Shandong Weigao Group Medical Polymer (SEHK:1066) just held an Extraordinary General Meeting, where shareholders approved an interim dividend and a series of amendments to its articles of association. These decisions could shape investor outlook in the coming months. See our latest analysis for Shandong Weigao Group Medical Polymer. After announcing both an interim dividend and a fresh round of governance amendments, Shandong Weigao Group Medical Polymer’s share price closed at HK$5.63...
SEHK:1883
SEHK:1883Telecom

A Fresh Look at CITIC Telecom (SEHK:1883) Valuation Following New Group Financial Services Agreements

CITIC Telecom International Holdings (SEHK:1883) has kicked off a series of new financial services framework agreements with CITIC Bank and CITIC Finance. These agreements set out how financial services will be managed within the group, depending on regulatory clearances and official sign-off from both sides. See our latest analysis for CITIC Telecom International Holdings. Shares of CITIC Telecom International Holdings have started to build some momentum after a subdued stretch, with a 6.96%...
SEHK:1142
SEHK:1142Trade Distributors

E&P Global Holdings (SEHK:1142): Evaluating Valuation After Sudden Chairman Exit on Regulatory Oversight Concerns

E&P Global Holdings (SEHK:1142) just made headlines with a swift shake-up at the top. The company’s chairman, Mr. Lee Jaeseong, resigned after failing to inform the Board about a key regulatory decision. See our latest analysis for E&P Global Holdings. After a blockbuster run earlier this year, E&P Global Holdings has seen momentum stall with a sharp pullback in recent weeks, underscored by volatility around the chairman’s exit and ongoing regulatory concerns. Despite a steep 43.97% share...
SEHK:1093
SEHK:1093Pharmaceuticals

How Breakthrough Therapy Status for JSKN003 at CSPC Pharmaceutical Group (SEHK:1093) Has Changed Its Investment Story

Alphamab Oncology and CSPC Pharmaceutical Group announced the receipt of another breakthrough therapy designation in China for their jointly developed HER2-targeting antibody-drug conjugate JSKN003, intended for treating advanced colorectal cancer. This regulatory recognition highlights JSKN003’s promising efficacy and safety profile, potentially accelerating its path to market in a high-need therapeutic area. We’ll explore how regulatory acceleration for promising oncology therapies such as...
SEHK:1931
SEHK:1931Healthcare

IVD Medical Holding (SEHK:1931) Valuation in Focus as It Unveils US Stablecoin and Digital Finance Ambitions

IVD Medical Holding (SEHK:1931) is making a bold move into digital finance with plans for a US headquarters focused on stablecoin blockchain research and a new platform for drug intellectual property securitization. See our latest analysis for IVD Medical Holding. IVD Medical Holding’s share price has surged in 2024, with a year-to-date gain of 432.77% and a remarkable 90-day climb of 180.65%. This signals surging momentum and heightened investor confidence following its expansions into...
SEHK:2171
SEHK:2171Biotechs

Could CARsgen (SEHK:2171) Redefine Its Innovation Edge After New Solid Tumor CAR T-Cell Data?

CARsgen Therapeutics Holdings presented Phase Ib clinical results for its CAR T-cell therapy satri-cel in Claudin18.2-positive pancreatic cancer at the ESMO Congress 2025, showing an 83.3% nine-month disease-free survival rate and a manageable safety profile. This trial marks the first proof-of-concept study for CAR T-cell therapy in the adjuvant solid tumor setting, highlighting CARsgen's advancement in innovative cancer therapeutics. We'll examine how these proof-of-concept clinical...
SEHK:688
SEHK:688Real Estate

Is September’s Sales Growth Shifting the Investment Outlook for China Overseas Land & Investment (SEHK:688)?

China Overseas Land & Investment announced that for September 2025, contracted property sales reached approximately RMB 20.17 billion, up 7.2% from the previous year, while the sales area declined by 3.7% year-on-year. This improvement in monthly sales performance stands out against a backdrop of a 14.3% year-to-date decline in contracted property sales through the first nine months of 2025. We'll explore what this September sales growth means for China Overseas Land & Investment's...